ClearPoint Neuro, Inc. (CLPT)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1285550 · fiscal year ends in Dec
Closing price $10.67 on 30 Oct 2026; 52-week range $8.66 to $23.68.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $45.5M
- Revenue growth
- 32.5%
- Net income, last twelve months
- -$36.1M
- Earnings per share
- -$1.20
- Gross margin
- 61.4%
- Operating margin
- -70.6%
- Net margin
- -79.4%
- Free cash flow
- -$48.2M
- Return on equity
- -132.5%
- Market value
- $342.0M
- Cash
- $46.2M
- Debt
- $50.8M
- Debt to equity
- 1.86
- Shares outstanding
- 32.1M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $37.0M | -$24.2M | -$25.5M | -$0.90 | -$24.4M | 10-K filed 17 Mar 2026 |
| FY2024 | 31 Dec 2024 | $31.4M | -$19.7M | -$18.9M | -$0.70 | -$9.2M | 10-K filed 26 Feb 2025 |
| FY2023 | 31 Dec 2023 | $24.0M | -$22.4M | -$22.1M | -$0.90 | -$14.4M | 10-K filed 12 Mar 2024 |
| FY2022 | 31 Dec 2022 | $20.6M | -$16.3M | -$16.4M | -$0.68 | -$16.4M | 10-K filed 1 Mar 2023 |
| FY2021 | 31 Dec 2021 | $16.3M | -$13.4M | -$14.4M | -$0.69 | -$12.9M | 10-K filed 9 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sep 2026 | $12.1M | -$7.5M | -$0.24 |
| Q2 FY2026 | 30 Jun 2026 | $10.9M | -$11.3M | -$0.38 |
| Q1 FY2026 | 31 Mar 2026 | $12.1M | -$9.6M | -$0.32 |
| Q4 FY2025 | 31 Dec 2025 | $10.4M | -$7.8M | -$0.26 |
| Q3 FY2025 | 30 Sep 2025 | $8.9M | -$5.9M | -$0.21 |
| Q2 FY2025 | 30 Jun 2025 | $9.2M | -$5.8M | -$0.21 |
| Q1 FY2025 | 31 Mar 2025 | $8.5M | -$6.0M | -$0.22 |
| Q4 FY2024 | 31 Dec 2024 | $7.8M | -$5.4M | -$0.20 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Product revenue | $23.9M | 64.5% |
| Service and other revenue | $13.1M | 35.5% |
Company events
The newest 8-K filings of 204 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 28 Oct 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 3 Aug 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 21 May 2026 | 8-K | Leadership change, Shareholder vote | 5.02, 5.07, 9.01 |
| 13 May 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 17 Mar 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 12 Jan 2026 | 8-K | Results | 2.02, 9.01 |
| 5 Jan 2026 | 8-K | Material agreement, New debt | 1.01, 2.03 |
| 20 Nov 2025 | 8-K | Deal completed, Material agreement, Share sale, Investor update | 1.01, 2.01, 3.02, 7.01, 9.01 |
| 6 Nov 2025 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 6 Nov 2025 | 8-K | Material agreement, Investor update | 1.01, 7.01, 9.01 |
| 12 Aug 2025 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 17 Jun 2025 | 8-K | Material agreement | 1.01, 9.01 |
Every filing
The newest filings with the SEC of 457 held.
| Filed | Form | Period |
|---|---|---|
| 28 Oct 2026 | 10-Q | 30 Sep 2026 |
| 28 Oct 2026 | 8-K | 28 Oct 2026 |
| 3 Aug 2026 | 10-Q | 30 Jun 2026 |
| 3 Aug 2026 | 8-K | 3 Aug 2026 |
| 21 May 2026 | 8-K | 20 May 2026 |
| 20 May 2026 | S-8 | – |
| 13 May 2026 | 10-Q | 31 Mar 2026 |
| 13 May 2026 | 8-K | 13 May 2026 |
| 23 Apr 2026 | ARS | 31 Dec 2025 |
| 23 Apr 2026 | DEFA14A | – |
| 10 Apr 2026 | DEF 14A | 10 Apr 2026 |
| 17 Mar 2026 | 10-K | 31 Dec 2025 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 29 Jun 2026 | Burnett Joseph, CEO and President | Sale under a trading plan | 20,000 | $19.38 | $387.6K | 116,842 | 1 Jul 2026 |
| 17 Jun 2026 | Burnett Joseph, CEO and President | Sale under a trading plan | 60,000 | $17.79 | $1.1M | 116,842 | 22 Jun 2026 |
| 17 Jun 2026 | Burnett Joseph, CEO and President | Sale under a trading plan | 1,843 | $17.94 | $33.1K | 191,388 | 22 Jun 2026 |
| 1 Jun 2026 | Richards Timothy T., Director | Sale outside a trading plan | 5,415 | $12.17 | $65.9K | 87,198 | 2 Jun 2026 |
| 21 May 2026 | Klein Matthew B., Director | Sale outside a trading plan | 16,000 | $11.59 | $185.4K | 46,935 | 26 May 2026 |
| 20 May 2026 | Fallon Lynnette C, Director | Sale under a trading plan | 5,091 | $11.14 | $56.7K | 48,227 | 21 May 2026 |
| 25 Feb 2026 | Burnett Joseph, CEO and President | Sale under a trading plan | 19,951 | $15.17 | $302.7K | 193,231 | 26 Feb 2026 |
| 26 Jan 2026 | Burnett Joseph, CEO and President | Sale under a trading plan | 2,943 | $15.57 | $45.8K | 214,116 | 27 Jan 2026 |
| 9 Jan 2026 | Burnett Joseph, CEO and President | Sale under a trading plan | 20,000 | $16.12 | $322.4K | 11,565 | 13 Jan 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 29 Jun 2026 | JOSEPH BURNETT, Director, Officer | 20,000 | $369.6K | 29 Jun 2026 |
| 17 Jun 2026 | JOSEPH M BURNETT TRUST, Affiliate of Director | 1,843 | $24.6K | 17 Jun 2026 |
| 17 Jun 2026 | JOSEPH BURNETT, Director, Officer | 60,000 | $800.4K | 17 Jun 2026 |
| 1 Jun 2026 | TIMOTHY RICHARDS, Director | 5,145 | $62.6K | 1 Jun 2026 |
| 29 May 2026 | PASCAL E. GIRIN, Director | 66,679 | $836.5K | 29 May 2026 |
| 21 May 2026 | MATTHEW B KLEIN, Director | 16,000 | $185.4K | 21 May 2026 |
| 20 May 2026 | LYNNETTE C FALLON, Director | 5,091 | $56.9K | 20 May 2026 |
| 25 Feb 2026 | JOSEPH M BURNETT TRUST, Affiliate of Director | 21,794 | $317.1K | 25 Feb 2026 |
| 26 Jan 2026 | JOSEPH M BURNETT TRUST, Affiliate of Director | 2,943 | $46.1K | 26 Jan 2026 |
| 9 Jan 2026 | JOSEPH M BURNETT, Director, Officer | 20,000 | $306.2K | 9 Jan 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 12 Aug 2026 | MAK CAPITAL ONE LLC | 13G amended | 7.8% | 2.4M |
| 4 Aug 2026 | BIGGER CAPITAL FUND L P | 13G amended | 7.45% | 2.3M |
| 27 Jul 2026 | BlackRock, Inc. | 13G amended | 7.1% | 2.1M |
| 15 May 2026 | MAK Capital Fund LP | 13G amended | 6.3% | 1.9M |
| 20 Apr 2026 | BIGGER CAPITAL FUND L P | 13G amended | 7.54% | 2.3M |
| 26 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 13 Mar 2026 | MAK Capital Fund LP | 13G | 6.1% | 1.7M |
| 4 Feb 2026 | BIGGER CAPITAL FUND L P | 13G amended | 7.8% | 2.2M |
| 12 Nov 2025 | BIGGER CAPITAL FUND L P | 13G amended | 7.6% | 2.1M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 4.6M | -2.8% | 6.58 |
| 30 Sep 2026 | 4.8M | +9.99% | 6.01 |
| 15 Sep 2026 | 4.3M | +3.3% | 6.92 |
| 31 Aug 2026 | 4.2M | -6.78% | 8.55 |
| 14 Aug 2026 | 4.5M | +15.46% | 5.89 |
| 31 Jul 2026 | 3.9M | +5.39% | 7.51 |
| 15 Jul 2026 | 3.7M | -14.08% | 7.93 |
| 30 Jun 2026 | 4.3M | -12.55% | 2.78 |
Funds that hold it
From each fund's latest Form 13F.
140 funds held it at 30 Jun 2026: 65 added and 30 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 2,379,804 | $42.5M | +297,054 |
| Mak Capital One LLC | 2,375,861 | $42.4M | +474,372 |
| Vanguard Capital Management LLC | 1,232,807 | $22.0M | -10,808 |
| State Street Corp. | 816,547 | $14.6M | +136,728 |
| Geode Capital Management, LLC | 749,932 | $13.4M | +44,212 |
| Lane Generational LLC | 444,831 | $7.9M | -42,018 |
| UBS Group AG | 428,632 | $7.6M | -3,728 |
| Millennium Management LLC | 357,676 | $6.4M | +125,702 |
| Brown Advisory Inc. | 325,906 | $5.8M | 0 |
| Compass Financial Management LLC | 295,680 | $5.3M | – |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $26.3B, market value $110.9B
- 3M Co. (MMM): revenue $25.2B, market value $90.1B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $60.8B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $53.9B
- Medline Inc. (MDLN): revenue –, market value $42.2B
- Resmed Inc. (RMD): revenue $5.7B, market value $32.3B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $30.7B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $28.8B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.1B
- Solventum Corp. (SOLV): revenue $8.3B, market value $13.8B